Drug-induced valvular heart disease (VHD) is a serious side effect linked to long-term treatment with 5-hydroxytryptamine (serotonin) receptor 2B (5-HT 2B ) agonists. Safety assessment for off-target pharmacodynamic activity is a common approach used to screen drugs for this undesired property. Such studies include in vitro assays to determine whether the drug is a 5-HT 2B agonist, a necessary pharmacological property for development of VHD. Measures of in vitro binding affinity (IC 50 , K i ) or cellular functional activity (EC 50 ) are often compared to maximum therapeutic free plasma drug levels (fC max ) from which safety margins (SMs) can be derived. However, there is no clear consensus on what constitutes an appropriate SM under various therapeutic conditions of use. The strengths and limitations of SM determinations and current risk assessment methodology are reviewed and evaluated. It is concluded that the use of SMs based on K i values, or those relative to serotonin (5-HT), appears to be a better predictor than the use of EC 50 or EC 50 /human fC max values for determining whether known 5-HT 2B agonists have resulted in VHD. It is hoped that such a discussion will improve efforts to reduce this preventable serious drug-induced toxicity from occurring and lead to more informed risk assessment strategies.
Since the initial descriptions in the 1960s linking development of valvular heart disease (VHD) with the use of the ergot derivatives methysergide and ergotamine to treat migraine (Bhattacharyya et al. 2009 ; Cavero and Guillon 2014), additional drugs have been identified with having VHD as a possible side effect associated with their long-term use. Although most of these drugs have since been withdrawn, some (e.g., cabergoline, dihydroergotamine, lorcaserin, pergolide) are still on the market with appropriate warnings in their labels. The one common feature linking these drugs to this serious and sometimes fatal outcome is their agonist activity for the 5-hydroxytryptamine (serotonin) receptor 2B (5-HT 2B ; Setola et al. 2003; ; Cavero and Guillon 2014). The 5-HT 2B is a G-protein-coupled receptor (GPCR) expressed by a wide variety of cell types, and its expression on cardiac valve leaflets is important for cardiac development and in maintaining normal cardiac valve structure and function. However, the sustained overstimulation of 5-HT 2B either by high plasma levels of serotonin or by drugs with 5-HT 2B agonist properties * This is an opinion article submitted to the Regulatory Forum and does not constitute an official position of the Society of Toxicologic Pathology or the journal Toxicologic Pathology. This article reflects the views of the authors and should not be construed to represent Food and Drug Administration's views or policies. The Regulatory Forum is designed to stimulate broad discussion of topics relevant to regulatory issues in toxicologic pathology. Readers of Toxicologic Pathology are encouraged to send their thoughts on these articles or ideas for new topics to regulatoryforum@toxpath.org.
can lead to development of VHD by stimulating myofibroblast mitogenesis and extracellular matrix deposition that eventually result in thickened valve leaflets, regurgitation due to improper closing during diastole, pulmonary hypertension, and eventually heart failure (Elangbam 2010; Hutcheson et al. 2011; Cavero and Guillon 2014) .
Most new drugs submitted to regulatory agencies generally undergo an assessment for secondary or off-target pharmacodynamic activity in vitro against a broad range of potential targets that are related to or distinct from the intended or primary therapeutic target (Whitebread et al. 2005; Bass et al. 2009; Bowes et al. 2012; Papoian et al. 2015) . Initial assessments include receptor binding studies; but if significant binding activity is detected, then follow-up cell-based functional assays are usually conducted to determine whether the drug acts as an agonist or antagonist for that target. In the case of the 5-HT 2B , such functional assays are important to determine whether the drug possesses 5-HT 2B agonist activity, a necessary pharmacological property for development of VHD. When in vitro data suggest such activity, the likelihood of risk under clinically relevant conditions and drug exposures is carefully assessed in a regulatory context, and safety recommendations made for the proposed clinical studies, or additional nonclinical studies requested to help better understand or reduce the risk.
A common approach for assessing risk to humans for drugs with possible off-target activity is to compare measures of in vitro binding or functional activity using human-specific targets to therapeutic free plasma drug levels seen in animals or to levels seen in humans once that data become available. From such a comparison, a safety margin (SM) can be derived, which is defined as the ratio of values of activity in vitro (IC 50 , K i , or EC 50 ) to the maximum therapeutic free plasma drug concentration in vivo (fC max ; Bowes et al. 2012; Muller and Milton 2012) . Such an approach has been described previously for several targets critical for proper cardiac function. These include (1) the human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG or I Kr ), whose inhibition has been linked to development of drug-induced QT interval prolongation and the appearance of torsade de pointes (Redfern et al. 2003), (2) the human cardiac Na þ channel (hNav1.5), whose inhibition can prolong the QRS interval and slow cardiac conduction (Harmer, Valentin, and Pollard 2011; Bowes et al. 2012) , and (3) the human 5-HT 2B receptor whose activation has been associated with development of VHD (Whitebread et al. 2005 ; Cavero and Guillon 2014). Generally, for hERG and hNav1.5a, a 30-to 100-fold ratio of IC 50 values to maximum human free plasma drug concentrations (fC max ) appears to confer an acceptable margin of safety for most drugs, whereas a 10-fold SM may be acceptable for drugs intended to treat some life-threatening indications. However, in the case of the 5-HT 2B , there still appears to be no clear consensus on what constitutes an appropriate SM under various therapeutic conditions of use. This is further complicated by the existence of multiple cell-based assay end points for measuring agonist activity ) and lack of standardized assay protocols (Cavero and Guillon 2014).
The purpose of this article is to provide a regulatory perspective on the current utility of in vitro secondary pharmacology data for the 5-HT 2B receptor to assess risk of drug-induced VHD in humans. It focuses on the current assay methodology, strengths and limitations of SM determinations, and approaches used by the various stakeholders for assessing risk for development of VHD with 5-HT 2B agonists. It is our hope that such a discussion will improve efforts to reduce the likelihood of this preventable and serious drug-induced toxicity from occurring and lead to more informed risk assessment strategies.
Roles of 5-HT (serotonin) and 5-HT 2B Signaling in Development of VHD
In mammalian species, vascular (semilunar aortic and pulmonary) and atrioventricular (mitral and tricuspid) heart valves maintain unidirectional blood flow across the heart chambers.
Valvular abnormalities, either genetic or acquired through a variety of etiologies, can lead to hemodynamic overload of the ventricles, myocardial dysfunction, congestive heart failure, and sudden death.
Early evidence implicating 5-HT 2B receptors in some acquired forms of VHD came from the association of certain carcinoid tumors secreting a variety of bioactive products, including 5-HT (serotonin), with subsequent development of VHD. Later, valvulopathy was shown to occur following longterm exposure to various drugs with 5-HT 2B agonist activity 5-HT has a complex role in both normal and pathological processes (Hutcheson et al. 2011 ). 5-HT produces its effects through a variety of ion channels and receptors that are found in the cardiovascular system, blood, gastrointestinal tract, and central and peripheral nervous systems. Up to fifteen 5-HT receptor subtypes have been characterized (Cavero and Guillon 2014) . Other than the 5-HT 3 receptor, which is a ligand-gated ion channel, the remaining 5-HT receptors belong to the GPCR superfamily. The 3 major 5-HT receptor subtypes (A, B, and C) are coupled primarily to the G q protein family. Activation of the 5-HT receptor results in dissociation of the heterotrimeric G protein complex into a Ga subunit that then activates phospholipase C. This leads to generation of intracellular signaling pathways involving inositol trisphosphate/calcium and diacyl glycerol/protein kinase C (PKC).
The development of drug-induced VHD is likely to be a manifestation of complex interactions among various factors, including endogenous 5-HT levels, 5-HT 2B density on valve leaflets, the serotonin transporter, and polymorphisms in individual gene expression. Often patients have comorbidities and receive concomitant therapies that, through metabolic or other interactions, can increase the normally low exposure of a 5-HT 2B agonist to a toxic level. Also, other drugs, such as those that increase 5-HT levels through impaired 5-HT metabolism or inhibition of the transmembrane 5-HT transporter, can become a reasonable safety concern when combined with a 5-HT 2B agonist.
The clinical diagnosis of drug-induced VHD is most commonly assessed with echocardiography. Characteristic features include valve leaflet thickening, restriction of motion of one or more valve leaflets, and distortion and thickening of the subvalvar apparatus, typically of the mitral valve (Andrejak and Tribouilloy 2013). These pathologic changes contribute to regurgitant blood flow. Recently, some authors have suggested that more rigorous criteria are needed to diagnose drug-induced VHD, such as using an integrative approach combining both color Doppler and valvular morphological characteristics, and pathologic findings, if available, to arrive at a more accurate diagnosis (Cosyns and Droogmans 2015) .
Assessment of Drugs for 5-HT 2B Receptor Agonist Activity
Evidence implicating 5-HT 2B in drug-induced VHD has come from multiple reports showing that activation of the receptor on heart valve interstitial cells is mitogenic, resulting in phosphorylation of extracellular signal-regulated kinase 1/2 (ERK 1/2) and the cytoplasmic tyrosine kinase sarcoma (Src) and activation of PKC with subsequent cellular proliferative responses and deposition of extracellular matrix material (Hutcheson et al. 2011 ).
Accordingly, various in vitro and animals models have been developed to determine whether drugs possess 5-HT 2B receptor agonist activity. These are described as follows:
Radioligand binding assays: Performed using intact cell or cell membrane preparations expressing human 5-HT 2B receptors, and results expressed as follows:
(a) Affinity (K i or inhibitory dissociation constant) of a compound for 5-HT 2B is determined by competition displacement binding of a selective 5-HT 2B radioligand by the test compound. An IC 50 is determined that can then be converted to K i values using the Cheng-Prusoff equation (Cheng and Prusoff 1973 ). (b) Kinetic binding assays are performed to calculate association (k on ) and dissociation (k off ) rates of test compounds to cell membrane preparations ). The dissociation constant (K d ) for the ligand is determined by the equation:
These binding assays cannot identify agonist or antagonistic properties of the test compound. Such properties are determined only by various functional assays, including those that are cell based, as described below. Results showed morphological and echocardiographic changes in aortic and pulmonary valve insufficiency similar to those seen in human carcinoid heart disease, including shortened and thickened aortic cusps and carcinoid-like plaques characterized by myofibroblasts within an extracellular matrix of collagen ground substance. An animal model of drug-induced VHD was first reported in the Wistar rat exposed to the serotonergic drug pergolide, given intraperitoneally at 0.5 mg/kg/day for 20 weeks (Droogmans et al. 2009 ). At the end of treatment, pergolide-treated rats developed valvular lesions, as assessed by echocardiography and histopathology, with features very similar to those described in humans. Use of cyproheptadine, a 5-HT 2B receptor antagonist, prevented the development of pergolide-induced valvular lesions in this rat model. Such animal models have shown utility in assessing the in vivo risk of druginduced VHD during the drug development and regulatory review processes.
Regulatory Considerations for Risk Assessment of Drugs with 5-HT 2B Agonist Activity
Given the well-described association of drugs with 5-HT 2B agonist activity as a risk factor for VHD, safety assessments typically performed by pharmaceutical companies during early drug development include 5-HT 2B binding studies for determination of any potentially significant off-target activity, and if a significant K i or IC 50 value is identified (typically <10 mM), then follow-up functional assays in cell-based systems may be performed to determine whether or not the drug possesses 5-HT 2B agonist activity, a necessary characteristic for a drug to produce VHD. However, as discussed further below, there appears to be significant variability in the ability of different in vitro cellular functional assays to be able to distinguish between those 5-HT 2B agonists that produce VHD from those 5-HT 2B agonists that do not when compared at clinically relevant exposures and conditions of use; that is, no consistent pattern of predictivity emerges. (Table 1) . Further, in a study that screened nearly 2,200 U.S. Food and Drug Administration (FDA)-approved and investigational drugs and drug-like scaffolds (i.e., molecular frameworks) for potential to induce VHD using calciumbased high-throughput screening, 27 were shown to be 5-HT 2B receptor agonists and included the 7 known valvulopathogens ). This later study demonstrated that no single pattern of functional selectivity using multiple assays could distinguish known valvulopathic 5-HT 2B agonists from nonvalvulopathic 5-HT 2B agonists. However, the authors suggested the need to perform multiple functional assays to screen compounds for possible 5-HT 2B agonist activity.
These findings suggest that the experimental conditions or protocols for determining 5-HT 2B agonist activity in cell-based functional assays are somewhat variable, and efforts to address these issues appear to be limited due to lack of available resources within various research groups both public and private (Cavero and Guillon 2014). Importantly, current cellbased functional assays alone for derivation of EC 50 values do not appear to be able to distinguish between 5-HT 2B agonists that produce VHD in humans from those agonists that do not ( Table 1 ). In light of the demonstrated variability in current cell-based functional assays, consideration of additional factors, such as inherent binding constants (K i ), maximum plasma free drug concentrations (fC max ), and duration of exposure (weeks to months), is necessary to assess whether a drug poses a significant risk for development of VHD in humans.
To explore this issue in more detail, we examined whether reported binding affinity data (K i ) for 5-HT 2B receptors, K i relative to human fC max , and K i relative would more closely correlate with the potential of a compound to be valvulopathic when compared to data from cell-based functional assays. We found that for all of the known 7 valvulopathic compounds, the K i values for the 5-HT 2B receptor are close to or less than an order of magnitude (i.e., <10Â) relative to the K i values of 5-HT (Table 2 ). In contrast, there is a >100-fold difference in K i values for the nonvalvulopathic 5-HT 2B agonist ropinirole relative to the K i values of 5-HT, even though results of functional assays give a strong signal for it to be valvulopathic (Table 1) . Further, there did not appear to be a good correlation between a drug's K i and its fC max values (K i /fC max ratio) for predicting whether a drug has the potential to produce VHD ( Table 2 ).
For compounds whose K i lies between 10-fold and 100-fold of 5-HT, such as lorcaserin, additional testing or clinical monitoring may still be required. Although the current label for lorcaserin contains a warning about possible valvulopathy based on in vitro binding data and early clinical trials, the postmarketing database of spontaneous MedWatch reports submitted to the FDA thus far do not add additional evidence of VHD with its use (unpublished data). The adjusted reporting ratio or data mining signal scores of the association of this drug with VHD overlap the ones from known negative controls. In addition, all the cases reported describe underlying conditions and risk factors, including cardiovascular diseases, diabetes, and obesity in elderly patients that preclude making, thus far, a causal relationship with this drug (Szarfman, Machado, and O'Neill 2002) .
Taken together, and in general agreement with recent reports (Cavero and Guillon 2014; Whitebread et al. 2016), these sets of data, although limited, suggest that the inherent binding potency (i.e., K i ) of a compound for the 5-HT 2B receptor, and in relation to that of 5-HT, gives a better indication of VHD risk than does potency of functional activity (i.e., EC 50 or EC 50 /human fC max ; Table 1 ), provided a compound is identified as a 5-HT 2B agonist in cell-based assays and is intended to be administered for a prolonged period of time (i.e., weeks to months or longer).
In summary, given the current difficulty in using functional assays to distinguish known valvulopathic drugs from those not known to produce VHD, and the inconsistency in deriving SMs based on EC 50 /human fC max ratios, use of 5-HT 2B receptor affinity or that relative to 5-HT should be considered as an initial risk assessment for VHD. To minimize variability, such binding assays for 5-HT 2B may choose to include 5-HT as an internal control to better correlate a drug's K i to the K i of 5-HT. Although the K i of a drug relative to 5-HT provides the same degree of prediction as the drug's K i itself, having a value relative to 5-HT may provide a useful reference point for assessing potency ( Table 2) .
These recommendations for assessing human risk are based on the assumptions that for a drug to be considered a possible risk for VHD under therapeutic conditions, it (1) shows an affinity to 5-HT 2B that is within an order of magnitude (<10Â) to that of 5-HT, (2) is positive for 5-HT 2B agonist activity in more than one cell-based functional assay, and (3) (14) 0.17-0.3 0.042-0.37 (6, 7, 13) 0.3-3.17 (6, 7, 10, 13) 0.025 (7) 2.17 (7) 0.25 (7) Ergotamine (13) 75.19 (7) 16.67 (13) 11.36 (7) 50 (7) 10.2 (7) Cabergoline Yes 2 (11) 1.25 (1,2)
1.59 (5) 0.8-1.25 125 (7) 250 (13) 4.17 (7) 0.47 (13) 2.20 (7) 5.18 (7) 5.71 (7) Ergonovine (ergometrine) Yes Plasma protein bound data are not available. C max total was used to calculate the human plasma levels for ergonovine and methylergonovine.
is indicated for long-term clinical use (i.e., weeks to months or longer). From a regulatory perspective, additional data or analyses may be needed to confirm these correlations, and ongoing efforts to standardize experimental conditions or protocols for determining 5-HT 2B agonist activity in a consistent and reproducible manner in human cell-based functional assays should continue.
Relatively simple and reproducible cell-based assays can provide meaningful information on the degree of 5-HT 2B agonist activity of a potential therapeutic that can then be better correlated with in vivo exposure once that data become available. 
Possible Utility of in Silico Predictions
In silico methods based on chemoinformatics, shape signatures, or quantitative structure-activity relationships have the potential to offer a faster and more efficient method for predicting drugs with 5-HT 2B receptor binding activity with a relatively high degree of confidence (Reid, Kumar, and Wang 2013; Garcia-Serna et al. 2015). Further, their ability to determine whether a drug is an agonist or not appears to depend on particular motifs of the molecule (Reid, Kumar, and Wang 2013). In a regulatory setting, in silico approaches are currently being used to predict possible adverse drug events postmarketing (Duggirala et al. 2015) . However, their utility for predicting off-target drug activity preclinically, or before human testing is initiated, has yet to be thoroughly evaluated. Such approaches, if feasible and validated, would allow early regulatory assessments of human risk beyond use of current in vitro secondary pharmacology studies. It could prove particularly useful for new molecular entities, first-in-class drugs, or drugs with active metabolites. In cases where binding or functional data for the 5-HT 2B are not available or difficult to obtain, in silico prediction methods may prove useful for assessing this critical target in certain situations.
Conclusions
There is general consensus that in vitro secondary pharmacology data provide a wealth of information relating to a drug's potential to produce pharmacodynamic activity unrelated to its intended mechanism of action. Such information is commonly generated by pharmaceutical companies during early drug development as a general screen for candidate drug selection and to assess potential safety risks of any selected drugs submitted to regulatory agencies for proposed investigational use in humans.
Drugs with agonist activity for the 5-HT 2B possess a clear risk for producing VHD, and it is essential that appropriate and relatively simple in vitro screening for this unwanted activity be conducted early. However, there does not appear to be a clear consensus on what constitutes an appropriate SM for drugs with 5-HT 2B agonist properties, in contrast to what others have proposed for drugs that block the cardiac hERG/I Kr and hNav1.5 channels (Redfern et al. 2003; Harmer, Valentin, and Pollard 2011). This difference may be attributable to inconsistencies in the various methods and end points assessed in 5-HT 2B -mediated cell-based functional assays among different laboratories, lack of standardized protocols, or simply due to inherent variability in cellular functional responses assessed in vitro. Although based on a limited data set of 5-HT 2B agonists with actual documented clinical experience, we believe that use of SMs based on K i values from binding assays or those relative to 5-HT K i values appears to be a better predictor than use of EC 50 or EC 50 /human fC max values from cellular functional assays for determining whether known 5-HT 2B agonists have resulted in VHD in humans. Although no clear cutoff value for an appropriate SM can be extrapolated from available published data, and other factors (e.g., intended duration of use and real or projected in vivo fC max values) need to be considered, use of 5-HT 2B receptor affinity (K i ) or that relative to 5-HT may prove useful for initial assessments of risk until cell-based functional assays for 5-HT 2B receptor agonist activity become standardized to allow more reliable use of EC 50 / human fC max ratio.
